Vagus nerve stimulation in the treatment of epilepsy
Payment policy perspectives
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published August 28, 2013.
Article Versions
- Previous version (August 28, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Saty Satya-Murti, MD, FAAN,
- Katie M. Shepard, BA and
- Sandra L. Helmers, MD, MPH, FAAN
- Saty Satya-Murti, MD, FAAN,
Between Jan 2011 and June 2013 participated in telephone consultations and/or in-person Medical Advisory Board meetings for: (1)Edwards LifeSciences 2011(2)United BioSource Corporation UBC (2010-13)(3)Bridgehead International (2011)(4)Medical Market Strategists (2012)(5)Pfizer(6) Simon-Kucher consultants (7)Stratas Consultants,(8) AstraZeneca (9) Avalere LLC
NONE
Travel expenses for some of the entities in Answer #1, except #7. (1)Edwards LifeSciences 2011(2)United BioSource Corporation UBC (2010-13)(3)Bridgehead International (2011)(4)Medical Market Strategists (2012)(5)Pfizer(6) Simon-Kucher consultants (7) AstraZeneca (8) Avalere LLC
NONE
NONE
NONE
Panelist, and later (2010-2011) Vice-Chair CMS-Medcac (Medicare Evidence Development and Coverage Advisory Committee). For the duration of the Medcac meeting, usually 1-2 days, I was considered an SGE (Special Government Employee).
(1)Edwards LifeSciences 2011(2)United BioSource Corporation UBC (2010-13)(3)Bridgehead International (2011)(4)Medical Market Strategists (2012)(5)Pfizer(6) Simon-Kucher consultants (7)Stratas Consultants,(8) AstraZeneca (9) Avalere LLC
NONE
Panelist, and later (2010-2011) Vice-Chair CMS-Medcac (Medicare Evidence Development and Coverage Advisory Committee). For the duration of the Medcac meeting, usually 1-2 days, I was considered an SGE (Special Government Employee).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katie M. Shepard, BA and
NONE
NONE
NONE
NONE
NONE
NONE
American Academy of Neurology, Associate Director Medical Economics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sandra L. Helmers, MD, MPH, FAAN
Cyberonics Scientific advisory board UCB Scientific advisory board
NONE
NONE
NONE
NONE
NONE
NONE
Cyberonics and UCB
NONE
NONE
I practice clinical epilepsy 43% of my time of about 10 % of my patients have vagus nerve stimulation.
Cyberonics multicenter health outcomes study UCB multicenter clinical trial UCB health outcomes research
CDC IPA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Health Policy Consultant (SS-M), Santa Maria, CA; American Academy of Neurology (KMS), Minneapolis, MN; and Emory University (SLH), Atlanta, GA.
- Correspondence to:
kshepard{at}aan.com
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.